New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
08:22 EDTABBVAbbVie ABT-199 data impressive, says BMO Capital
BMO Capital believes that data for Abbvie's ABT-199 drug was positive. The firm continues to find the drug impressive and raised its price target on the stock to $60 from $57. It keeps an Outperform rating on the shares.
News For ABBV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 30, 2015
07:32 EDTABBVJuno pact leaves Celgene set for growth past Revlimid, says Deutsche Bank
Subscribe for More Information
June 26, 2015
12:02 EDTABBVEMA adopts positive opinion on AbbVie's Humira for acne inversa
Subscribe for More Information
June 24, 2015
06:12 EDTABBVAbbVie announces new TURQUOISE-III study results
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use